In parallel, Zhou et al. [34] analyzed more than 56 million electronic health records and reported that treatment with TNF-α inhibitors, including etanercept, adalimumab, and infliximab, was associated with a significantly lower risk of AD among patients with rheumatoid arthritis and psoriasis. This evidence concerns the gene TNF and psoriasis.